Navigation Links
Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer


Measure mutations in any tissue with the Big Blue transgenic rodent mutation assay

Johan G. de Boer Barry W. Glickman
Centre for Environmental Health, University of Victoria, Victoria, BC Canada

With Stratagenes Big Blue transgenic rodent mutation assay,* which carries the E. coli lacI transgene in a retrievable chromosomally integrated shuttle vector, it is easy to study mutations in male and female mice or rats of any age under selected conditions in vivo. Multilab studies indicate that mutations are generally induced in the same tissue that tumors are produced but not in nontarget tissues. This makes the transgenic model for the study of genotoxicity even more valuable, since mutations can be studied in virtually any tissue.

The hallmark of occupational- and lifestyle-related cancer is tissue specificity. Human exposures to carcinogens result in particular types of cancer at predictable sites; tobacco smoke, arsenic, and ionizing radiation all produce their own unique kinds of cancers in preferred tissues. Tissue specificity is also a feature of animal model systems. For example, when male mice are exposed to the flame retardant tris(2,3-dibromopropyl)phosphate (TDBP), they contract kidney tumors, and the alkylating agent dimethylnitrosamine predominantly produces liver, kidney, and lung tumors. Sex can also have an impact on tissue targeting. In the case of TDBP, liver tumors predominate in female mice, while kidney tumors are seen in male mice.

Figure 1

This kind of information is crucial for identifying suspected carcinogens. Hence, we ask a critical question: Does mutation follow the same pattern as the targeting of tumors? In other words, are mutations being induced in tissues where tumors are recovered and not in others? Big Blue transgenic rodents with recoverable mutation target genes make use of the well-characterized bacterial lacI gene as a mutational target gene. The lacI gene, part of the lLIZ shuttle vector, is present in approximately 40 copies per chromosome in the mouse and rat. Mutations are efficiently assessed through the recovery of the l genome (Figure 1). High molecular weight genomic DNA is isolated from any selected Big Blue transgenic rodent tissue, which can be facilitated with the RecoverEase DNA isolation kit, and the l genomes are packaged into phage particles by Transpack lambda packaging extract.** The l particles are then plated on a specially constructed E. coli host in the presence of the chromogenic compound X-gal. Phages carrying the mutated lacI gene produce blue plaques, whereas the wild-type gene yields colorless plaques.

The ratio of blue to clear plaques indicates the mutant frequency, which in most tissues varies between 2 to 6 x 10-5, although it is often lower in the rat than the mouse. Subsequent sequencing of the mutant lacI genes reveals the specific nature of the DNA change at the molecular level; when a sufficient number of mutants have been sequenced, a mutational spectrum results. Mutational spectra are extremely useful in assessing the mechanism of mutation. DNA sequencing also permits the mutant frequency to be adjusted by allowing a correction for clonal expansion in which an individual mutation is recovered multiple times because of cell division.

Tissue Specific Effects

Researchers who have designed studies to assess mutations in a range of tissues after carcinogen treatment have addressed whether mutations are induced selectively in those tissues targeted for tumorigenesis. We reviewed some of the available data to illustrate how the Big Blue transgenic rodent mutagenesis assay system is used in tissue-specific studies (Table 1).

Table 1
Induction of Tumors and Mutations in Target and Nontarget Tissues by Selected Carcingens

Compound

Tumor target

Mutations

No mutations

DMN2,3

Liver, kidney, lung

Liver, kidney, lung

Bladder, bone marrow, testis

TDBP1

Kidney

Kidney, liver

Stomach

PhIP*

Colon

Colon

Liver

MeIQ10

Colon, liver, skin, mammary gland

Colon, liver, skin, mammary gland

Heart

Ethylene oxide7

lung

lung

Spleen, bone marrow, germ cells

Benzene8

Lung, leukemia, lymphomas

Lung, spleen

liver

* De Boer et al., unpublished
See text for additional details.

TDBP

The flame retardant tris(2,3-dibromopropyl)phosphate (TDBP) is an established kidney-specific carcinogen in male and female rats and male mice; in female mice, it targets the liver. In a TDBP study,1 the lacI mutation frequency was determined in the kidney, liver, and stomach of male Big Blue mice after treatment with 2000 ppm of TDBP. The mutant frequency increased marginally in the kidney and liver (approximately 50%) but not the stomach. Sequencing the mutants revealed a unique difference in mutational spectrum: The spectrum from the liver was indistinguishable from that of untreated animals, while that from the kidney included unique deletions of single GC base pairs. Thus, in this case, TDBP-specific mutations were induced only in the tissue where tumors were recovered. Hence, DNA sequencing can improve the assay sensitivity in situations where the induced mutant frequency is low.

DMN

Tissue specificity was also observed with dimethylnitrosamine (DMN), which has been well studied in the liver.2 DMN produces tumors in various organs including the liver, kidney, and lung. Suzuki et al.3 observed mutation induction in each of these tissues (6.2, 2.4, and 2.1 fold, respectively). In contrast, they observed no statistically significant mutation induction in nontarget tissues such as the urinary bladder (1.7 x 10-5 versus 1.4 x 10-5 in controls), testis (0.39 x 10-5 versus 0.48 x 10-5 in controls), and bone marrow (1.7 x 10-5 versus 1.3 x 10-5 in controls).

MeIQ

MeIQ (2-amino-3,4-dimethylimidazo[4,5-f ]quinoline) is a potent heterocyclic amine found in the human diet. MeIQ induces tumors in several rat tissues including colon, skin, mammary gland, oral cavity; in the mouse it forms tumors of the forestomach and liver. Several publications have shown that MeIQ induced mutations in Big Blue transgenic rodents.4,5 Induced mutations have been observed in each target tissue except the heart, which is not a target for tumorigenesis. Ushijima et al.5 determined the DNA sequence alterations in mutants recovered from the liver (approximately a 4.5-fold increase in mutant frequency) and bone marrow (approximately a 5-fold increase). A significant tissue-specific difference was seen in the mutant fractions that were GC to TA transversions: 37% in the liver versus only 14% in bone marrow. Consequently, both sequencing DNA and determining mutant frequency are important for more accurately assessing mutation induction and mechanism.

PhIP

PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) is a colon carcinogen in the male rat but does not cause tumors in the liver. It induced a 20-fold increase in colon mutations after 400 ppm PhIP was added to the diet.6 We recently determined that no mutations above background are induced in the liver of these animals (de Boer, et al., unpublished). DNA adducts are found in the colon but not the liver. PhIP is metabolically activated in the liver by cytochrome P450, but additional metabolic processing takes place in colon cells.

Ethyleneoxide and Benzene

Sisk et al.7 studied mutation induction in lacI transgenic mice after the mice inhaled 200 ppm of ethylene oxide. The mutant frequency increased significantly in the lung (9.1 x 10-5 versus 6.2 x 10-5 in the controls) but not the spleen, bone marrow, and male germ cells. The lung is indeed a major target organ for tumor formation in the mouse. In another mouse inhalation study with benzene,8 which induces lung tumors, leukemia, and lymphomas, mutations significantly increased in the lung and spleen (a 1.7- and 1.5-fold increase, respectively) but not in the liver tissue. Benzene metabolism takes place partially in the liver, while final oxidation steps can take place in the bone marrow.

Conclusions

The Big Blue transgenic rodent assay system accurately predicts mutations in specific tissues. In a number of cases, mutations are recovered in tissues that are not targets for carcinogenesis. While this eases the screening for mutagenic compounds, it becomes more difficult to determine mutagenic mechanisms and how they relate to carcinogenesis.9 For example, we recently determined that mutation induction in the kidney after TDBP treatment is highest in the cortex layer and less in the outer and inner medulla (de Boer, et al., in preparation). Tumors, however, do not arise in the cortex but in the outer medulla layer. This and other findings indicate that cell proliferation is equally important for tissue-specific tumor formation.

REFERENCES
  1. De Boer, J.G., et al.(1996) Environ. Mol. Mutagen. 28: 418-423.

  2. Mirsalis, J.C., et al.(1993) Mutagenesis 8: 265-271.

  3. Suzuki, T., et al. (1996) Environ. Mol. Mutagen. 28: 348-353.

  4. Suzuki, T., et al. (1996) Mutat. Res. 369: 45-49.

  5. Ushijima, T., et al. (1994) Carcinogenesis 15: 2805-2809.

  6. Okonogi, H., et al. (1997) Mutat. Res. 395: 93-99.

  7. Sisk, S.C., et al. (1997) Mutat. Res. 391: 153-164.

  8. Mullin, A.H., et al. (1995) Mutat. Res. 327: 121-129.

  9. Gorelick, N.J., (1996) Prog. Clin. Biol. Res. 395: 81-108.

  10. Ushijima, T., et al. (1994) Carcinogenesis 15: 2805-2809.

* U.S. Patent No. 5,347,075 and 5,589,155; European Patent No. 0289121;
Japanese Patent No. 2618973.
** U.S. Patent No. 5,188,957.


'"/>

Source:


Page: All 1 2 3 4 5 6 7

Related biology technology :

1. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
2. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
3. Simple Isolation of RNA from Tissue and Cultured Cells
4. Hands-free Tissue Disruption No Homogenization Needed
5. Recover High Yields of Total Nucleic Acid from Formalin-fixed, Paraffin-embedded (FFPE) Tissue
6. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
7. Stabilizing RNA in Fresh and Frozen Tissues for RNA Isolation
8. Genomic DNA Preparation from RNAlater Preserved Tissues
9. DNA Isolation From 300 to 450 mg Dried or 600 to 1,200 mg Fresh Leaf Tissue
10. DNA Isolation From 50 to 20 mg of Paraffin-Embedded Tissue
11. Genomic DNA Isolation From 510 mg Marine Invertebrate Tissue
Post Your Comments:
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... July 25, 2014 Research and ... "Global Metabolomics Market 2014-2018" report to their ... Metabolomics or Metabonomics is the scientific ... become a new experimental technique that is being ... sciences. Metabolites are small molecules that are present ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
Breaking Biology Technology:Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... May 11 Amicus Therapeutics (Nasdaq: ... Matthew R. Patterson, will be presenting at the upcoming Bank ... Mr. Patterson,s presentation is scheduled to begin on Wednesday, ... live webcast of the presentation by logging on to the ...
... NEW YORK, May 11 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... to,improving health through the development, manufacture and commercialization of,a ... products in China,today announced financial results for the first ... Financial Results , Revenue ...
... May 9 Oxford Biomedica,s,second attempt to dismiss Bavarian ... Instead of denying infringement, Oxford Biomedica,made yet another attempt ... TroVax(R) was still evaluated in clinical trials. The court ... based on the,substance of the patents. , ...
Cached Biology Technology:American Oriental Bioengineering Reports First Quarter 2009 Financial Results 2American Oriental Bioengineering Reports First Quarter 2009 Financial Results 3American Oriental Bioengineering Reports First Quarter 2009 Financial Results 4American Oriental Bioengineering Reports First Quarter 2009 Financial Results 5American Oriental Bioengineering Reports First Quarter 2009 Financial Results 6American Oriental Bioengineering Reports First Quarter 2009 Financial Results 7The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica 2
(Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
(Date:7/27/2014)... like bacteria and fungi can evade treatment by acquiring ... drugs. These permanent mutations were once thought to be ... a new study has shown that microorganisms can use ... epimutations -- to gain the benefits of drug resistance ... discovered in a fungus called Mucor circinelloides, it is ...
(Date:7/27/2014)... from over 18,000 patients, scientists have identified more ... Parkinson,s disease, including six that had not been ... Genetics , was partially funded by the National ... working in NIH laboratories. , "Unraveling the genetic ... multiple mechanisms involved in this complex disease, and ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... Just as scientists finished sequencing the human genome, they ... DNA produces proteins to sustain life, they found microRNA. ... channel in biology, allowing scientists to more closely examine ... tick. "This is a pivotal mechanism for solving ...
... Ore Oregon Health & Science University researchers, along ... uncovering new information about the mind by studying the ... this research will one day provide new tools for ... treatments. The researchers, latest findings are published in the ...
... Universit de Montreal (UdeM) and the Montreal Neurological Institute ... support nerve cell (neuron) survival also play an active ... the eye. The findings, published this week in The ... streamlined therapies for a variety of acute and chronic ...
Cached Biology News:Meet DNA's personal assistants 2OHSU researchers study the idling brain 2Cell's split personality is a major discovery into neurological diseases 2
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
... Cloning is the most ... cloning PCR products. TOPO ... Blunt TOPO vectors are ... with topoisomerase I. This ...
Applications: ISH...
... ZMD.420. Immunogen: Recombinant human ... Specific for the ~44 kDa ... Human (positive control: IFN-Gamma-stimmulated Human ... sequence homology reactivity with mouse ...
Biology Products: